ALXO - Company ID 0001810182
The table below shows ALX ONCOLOGY HOLDINGS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0.00 | $0.00 | $1.18M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $77.00M | $116.37M | $141.79M | $98.40M | $60.17M | $28.96M |
| SG&A |
ALX ONCOLOGY HOLDINGS INC reported annual revenue of $0.00 for fiscal year 2022. Over the 5 fiscal years shown, annual revenue declined from $2.07M (FY 2018) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $23.85M |
| $26.09M |
| $28.48M |
| $29.04M |
| $23.39M |
| $14.81M |
| Operating income | -$104.02M | -$142.47M | -$170.28M | -$127.44M | -$83.56M | -$43.66M |
| Income tax | $0.00 | $0.00 | $0.00 | $64.00K | -$21.00K | $241.00K |
| Net income | -$101.69M | -$134.85M | -$160.81M | -$123.48M | -$83.46M | -$45.74M |
| EPS (diluted) | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 |